Key result
Intravenous administration of NKH477 at 0.5 µg/kg/min significantly improved hemodynamic, subjective, and objective conditions in 70.4% of patients with acute heart failure compared to 26.7% in the lower-dose control group.
Why the study?
Does intravenous NKH477 improve hemodynamics and clinical conditions in patients with acute heart failure?
Population
62 patients with acute heart failure
Comparison
NKH477 intravenous administration at… vs Lower dose of NKH477 as a substitute placebo…
Design
RCT, randomly assigned, double-blind
Follow-up
up to 1.5 hours
Authors
Loading...
Supports intravenous NKH477 in acute HF; delivers first multicenter RCT evidence for this forskolin derivative.
RCT (n=62)
Double-blind
Randomized
Yes
Does intravenous NKH477 improve hemodynamics and clinical conditions in patients with acute heart failure?
Absolute Event Rate: 70.4% vs 26.7%
p-value: p=<0.01
Intravenous NKH477 significantly improves hemodynamic, subjective, and objective conditions in patients with acute heart failure compared to low-dose control or placebo.
Hosoda et al. (1997) conducted an RCT in Acute heart failure (n=62). NKH477 vs. Lower dose NKH477 (0.2 µg/kg/min) or placebo was evaluated on Percentage improvement in hemodynamic, subjective, and objective conditions (p=<0.01). Intravenous administration of NKH477 at 0.5 µg/kg/min significantly improved hemodynamic, subjective, and objective conditions in 70.4% of patients with acute heart failure compared to 26.7% in the lower-dose control group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: